To explore the value of dynamic contrast enhanced ultrasound (DCE-US) in preoperative differential diagnosis of focal-type autoimmune pancreatitis (AIP) and pancreatic ductal adenocarcinoma (PDAC).
PATIENTS AND METHODS:
From May 2016 to March 2020, patients with biopsy and histopathologically confirmed focal-type AIP (n = 9) were retrospectively included. All patients received contrast enhanced ultrasound (CEUS) examinations one week before surgery/biopsy. Dynamic analysis was performed by VueBox® software (Bracco, Italy). Eighteen cases of resection and histopathologically proved PDAC lesions were also included as control group. B mode ultrasound (BMUS) features, CEUS enhancement patterns, time intensity curves (TICs) and CEUS quantitative parameters were obtained and compared between AIP and PDAC lesions.
RESULTS:
After injection of ultrasound contrast agents, most focal-type AIP lesions displayed hyper-enhancement (2/9, 22.2%) or iso-enhancement (6/9, 66.7%) during arterial phase of CEUS, while most of PDAC lesions showed hypo-enhancement (88.9%) (P < 0.01). During late phase, most of AIP lesions showed iso-enhancement (8/9, 88.9%), while most of PDAC lesions showed hypo-enhancement (94.4%) (P < 0.001). Compared with PDAC lesions, TICs of AIP lesions showed delayed and higher enhancement. Among all CEUS perfusion parameters, ratio of PE (peak enhancement), WiAUC (wash-in area under the curve), WiR (wash-in rate), WiPI (wash-in perfusion index, WiPI = WiAUC/ rise time), WoAUC (wash-out area under the curve), WiWoAUC (wash-in and wash-out area under the curve) and WoR (wash-out rate) between pancreatic lesion and surrounding normal pancreatic tissue were significantly higher in AIP lesions than PDAC lesions (P < 0.05).
CONCLUSION:
DCE-US with quantitative analysis has the potential to make preoperative differential diagnosis between focal-type AIP and PDAC non-invasively.
HeC, RongD, HuW, CaiQ, YangQ, MaoY, et al. A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Cancer Med. 2019;8(14):6250–7.
ZhangQ, WuL, YangD, QiuY, YuL, DongY, et al. Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. Clin Hemorheol Microcirc. 2020;75(3):325–34.
7.
AbrahamSC, WilentzRE, YeoCJ, SohnTA, CameronJL, BoitnottJK, et al. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all ‘chronic pancreatitis’?Am J Surg Pathol. 2003;27(1):110–20.
8.
EL, XuY, WuZ, LiL, ZhangN, YangH, et al. Differentiation of Focal-Type Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma Using Radiomics Based on Multiphasic Computed Tomography. J Comput Assist Tomogr. 2020;44(4):511–8.
9.
HoriuchiA, KawaS, HamanoH, HayamaM, OtaH, KiyosawaK. ERCP features in 27 patients with autoimmune pancreatitis. Gastrointest Endosc. 2002;55(4):494–9.
10.
KwonJH, KimJH, KimSY, ByunJH, KimHJ, LeeMG, et al. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Eur Radiol. 2019;29(11):5763–71.
11.
LeeS, KimJH, KimSY, ByunJH, KimHJ, KimMH, et al. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Eur Radiol. 2018;28(12):5267–74.
12.
LerchMM, MayerleJ. The benefits of diagnostic ERCP in autoimmune pancreatitis. Gut. 2011;60(5):565–6.
ShimosegawaT, ChariST, FrulloniL, KamisawaT, KawaS, Mino-KenudsonM, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8.
15.
SchreyerAG, WesslingJ, GrenacherL. Current Practice vs. Guideline Based Imaging in Abdominal Radiology in the German Speaking Area: Results of an Online Survey. Rofo. 2016;188(3):268–79.
16.
SuzukiK, ItohS, NagasakaT, OgawaH, OtaT, NaganawaS. CT findings in autoimmune pancreatitis: assessment using multiphase contrast-enhanced multisection CT. Clin Radiol. 2010;65(9):735–43.
17.
TakahashiN, FletcherJG, HoughDM, FidlerJL, KawashimaA, MandrekarJN, et al. Autoimmune pancreatitis: differentiation from pancreatic carcinoma and normal pancreas on the basis of enhancement characteristics at dual-phase CT. AJR Am J Roentgenol. 2009;193(2):479–84.
18.
RehnitzC, KlaussM, SingerR, EhehaltR, WernerJ, BuchlerMW, et al. Morphologic patterns of autoimmune pancreatitis in CT and MRI. Pancreatology. 2011;11(2):240–51.
19.
HasebroockKM, SerkovaNJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol. 2009;5(4):403–16.
20.
GrenacherL, JuchemsMS, HolzapfelK, KinnerS, LauensteinTC, WesslingJ, et al. A Review of Scientific Topics and Literature in Abdominal Radiology in Germany–Part Abdominal Parenchymal Organs. Rofo. 2016;188(3):245–52.
ScialpiM, ReginelliA, D’AndreaA, GravanteS, FalconeG, BaccariP, et al. Pancreatic tumors imaging: An update. Int J Surg. 2016;28 Suppl 1:S142–55.
23.
NagpalSJS, SharmaA, ChariST. Autoimmune Pancreatitis. Am J Gastroenterol. 2018;113(9):1301.
24.
ClaudonM, CosgroveD, AlbrechtT, BolondiL, BosioM, CalliadaF, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall Med. 2008;29(1):28–44.
25.
D’OnofrioM, BarbiE, DietrichCF, KitanoM, NumataK, SofuniA, et al. Pancreatic multicenter ultrasound study (PAMUS). Eur J Radiol. 2012;81(4):630–8.
26.
PiscagliaF, NolsoeC, DietrichCF, CosgroveDO, GiljaOH, Bachmann NielsenM, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med. 2012;33(1):33–59.
27.
SidhuPS, CantisaniV, DietrichCF, GiljaOH, SaftoiuA, BartelsE, et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med. 2018;39(2):e2–e44.
28.
DietrichCF, AverkiouMA, CorreasJM, LassauN, LeenE, PiscagliaF. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med. 2012;33(4):344–51.
29.
WildnerD, SchellhaasB, StrackD, GoertzRS, PfeiferL, FiesslerC, et al. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS). Clin Hemorheol Microcirc. 2019;71(1):39–51.
30.
BeyerLP, WassermannF, PreglerB, MichalikK, RennertJ, WiesingerI, et al. Characterization of Focal Liver Lesions using CEUS and MRI with Liver-Specific Contrast Media: Experience of a Single Radiologic Center. Ultraschall Med. 2017;38(6):619–25.
31.
WiesingerI, WiggermannP, ZausigN, BeyerLP, SalzbergerB, StroszczynskiC, et al. Percutaneous Treatment of Malignant Liver Lesions: Evaluation of Success Using Contrast- Enhanced Ultrasound (CEUS) and Perfusion Software. Ultraschall Med. 2018;39(4):440–7.
32.
WiesingerI, JungF, JungEM. Contrast-enhanced ultrasound (CEUS) and perfusion imaging using VueBox(R). Clin Hemorheol Microcirc. 2021;78(1):29–40.
33.
NylundK, SaevikF, LehS, PfefferF, HauskenT, GiljaOH. Interobserver Analysis of CEUS-Derived Perfusion in Fibrotic and Inflammatory Crohn’s Disease. Ultraschall Med. 2019;40(1):76–84.
34.
SarlesH, SarlesJC, CamatteR, MuratoreR, GainiM, GuienC, et al. Observations on 205 confirmed cases of acute pancreatitis, recurring pancreatitis, and chronic pancreatitis. Gut. 1965;6(6):545–59.
35.
ManfrediR, FrulloniL, MantovaniW, BonattiM, GrazianiR, Pozzi MucelliR. Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology. 2011;260(2):428–36.
36.
AnderloniA, GencoC, BallareM, CarmagnolaS, BattistaS, RepiciA. A case of primary pancreatic non-Hodgkin B-cell lymphoma mimicking autoimmune pancreatitis. J Gastrointestin Liver Dis. 2015;24(2):245–8.
37.
HaJ, ChoiSH, ByunJH, KimKW, KimSY, KimJH, et al. Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma. Eur Radiol. 2021;31(5):3427–38.
38.
FuruhashiN, SuzukiK, SakuraiY, IkedaM, KawaiY, NaganawaS. Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT. Eur Radiol. 2015;25(5):1366–74.
39.
KimHJ, KimYK, JeongWK, LeeWJ, ChoiD. Pancreatic duct “Icicle sign” on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. Eur Radiol. 2015;25(6):1551–60.
40.
KimSS, ChoiGC, JouSS. Pancreas Ductal Adenocarcinoma and its Mimics: Review of Cross-sectional Imaging Findings for Differential Diagnosis. J Belg Soc Radiol. 2018;102(1):71.
41.
TakahashiN, FletcherJG, FidlerJL, HoughDM, KawashimaA, ChariST. Dual-phase CT of autoimmune pancreatitis: a multireader study. AJR Am J Roentgenol. 2008;190(2):280–6.
42.
ChoiEK, KimMH, LeeTY, KwonS, OhHC, HwangCY, et al. The sensitivity and specificity of serum immunoglobulin G and immunoglobulin G4 levels in the diagnosis of autoimmune chronic pancreatitis: Korean experience. Pancreas. 2007;35(2):156–61.
43.
GhazaleA, ChariST, SmyrkTC, LevyMJ, TopazianMD, TakahashiN, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol. 2007;102(8):1646–53.
44.
D’OnofrioM, BiagioliE, GerardiC, CanestriniS, RulliE, CrosaraS, et al. Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis. Ultraschall Med. 2014;35(6):515–21.
45.
FanZ, LiY, YanK, WuW, YinS, YangW, et al. Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions–a comparison of conventional ultrasound and contrast-enhanced CT. Eur J Radiol. 2013;82(9):1385–90.
46.
JungEM, StroszczynskiC, JungF. Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience. Clin Hemorheol Microcirc. 2020;74(4):353–61.
47.
JungEM, StroszczynskiC, JungF. Contrast enhanced ultrasound (CEUS) to assess pleural pulmonal changes in severe COVID-19 infection: First results. Clin Hemorheol Microcirc. 2020;75(1):19–26.
48.
FarleyTE, HowellSM, LoveKF, WolfeRD, NeumannCH. Meniscal tears: MR and arthrographic findings after arthroscopic repair. Radiology. 1991;180(2):517–22.
49.
AnandD, LallC, BhosaleP, GaneshanD, QayyumA. Current update on primary pancreatic lymphoma. Abdom Radiol (NY). 2016;41(2):347–55.
D’OnofrioM, CanestriniS, CrosaraS, De RobertisR, Pozzi MucelliR. Contrast enhanced ultrasound with quantitative perfusion analysis for objective characterization of pancreatic ductal adenocarcinoma: A feasibility study. World J Radiol. 2014;6(3):31–5.
53.
DongY, KochJBH, LoweAL, ChristenM, WangWP, JungEM, et al. VueBox(R) for quantitative analysis of contrast-enhanced ultrasound in liver tumors. Clin Hemorheol Microcirc. 2021.
54.
DongY, QiuY, YangD, YuL, ZuoD, ZhangQ, et al. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma. Clin Hemorheol Microcirc. 2021;77(4):461–9.
55.
DanZ, YiF, QiZ, Yi-JieQ, Xiao-FanT, Shuai-NanS, et al. The value of dynamic contrast enhanced ultrasound (DCE-US) in monitoring treatment effect of high-intensity focused ultrasound (HIFU) in locally advanced pancreatic cancer (LAPC). Clin Hemorheol Microcirc. 2020.
56.
KimJH, KimH, KimYJ, LeeJY, HanJK, ChoiBI. Dynamic contrast-enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer. Eur Radiol. 2014;24(9):2059–68.
57.
JungEM, ClevertDA, SchreyerAG, SchmittS, RennertJ, KubaleR, et al. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. World J Gastroenterol. 2007;13(47):6356–64.
58.
ChoiSY, KimSH, KangTW, SongKD, ParkHJ, ChoiYH. Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings. AJR Am J Roentgenol. 2016;206(2):291–300.
59.
HexigeS, Ardito-AbrahamCM, WuY, WeiY, FangY, HanX, et al. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. J Pathol. 2015;236(2):142–54.
